Fate Therapeutics, Inc.
2.44USD
-0.0600 (-2.40%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 96.3M | 63.5M | 13.6M | 6.6M | 5.6M | 4.8M |
| Q1 | 18.4M | 59.0M | 1.9M | 1.6M | 1.3M | — |
| Q2 | 18.5M | 933.0K | 6.8M | 1.9M | 2.1M | — |
| Q3 | 15.0M | 1.9M | 3.1M | 1.7M | 1.2M | — |
| Q4 | 44.4M* | 1.7M* | 1.9M* | 1.4M* | 1.2M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -2.91 | -1.64 | -1.64 | -1.15 | -1.02 | -.968 |
| Q1 | -.680 | -.190 | -.470 | -.320 | -.260 | — |
| Q2 | -.790 | -.540 | -.330 | -.290 | -.250 | — |
| Q3 | -.860 | -.460 | -.400 | -.270 | -.255 | — |
| Q4 | -.582* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.448* |
| -.459* |
| -.273* |
| -.270 |
| — |